OM

Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund" Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund declined by 2.7% in the first quarter of 2026 due to a sharp macro-driven sector rotation following geopolitical tensions, which triggered inflation fears and rising interest rate expectations. This scenario led to a shift in investor focus toward sectors such as energy, defense, and AI-linked stocks, while the fund’s core exposure to healthcare, consumer, and idiosyncratic industrials lagged. Despite this setback, the firm maintains a constructive long-term outlook, suggesting that the current market volatility and consensus-driven market narratives are creating attractive opportunities in out-of-favor sectors where it continues to find compelling valuations and expects eventual mean reversion to drive future returns. In addition, you can check the Fund’s top five holdings to determine its best picks for 2026. In its first-quarter 2026 investor letter, Minot Light Capital Appreciation Fund highlighted stocks like Outset Medical, Inc. (NASDAQ:OM). Outset Medical, Inc. (NASDAQ:OM) is a medical technology company focused on dialysis systems designed to simplify kidney treatment. The one-month return of Outset Medical, Inc. (NASDAQ:OM) was -11.72% while its shares traded between $3.00 and $21.98 over the last 52 weeks. On May 12, 2026, Outset Medical, Inc. (NASDAQ:OM) stock closed at approximately $3.84 per share, with a market capitalization of about $71.18 million. Minot Light Capital Appreciation Fund stated the following regarding Outset Medical, Inc. (NASDAQ:OM) in its Q1 2026 investor letter: Outset Medical, Inc. (NASDAQ:OM) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. As per our database, 22 hedge fund portfolios held Outset Medical, Inc. (NASDAQ:OM) at the end of the fourth quarter, which was 23 in the previous quarter. While we acknowledge the risk and potential of Outset Medical, Inc. (NASDAQ:OM) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best s...

Image source: The Motley Fool. Wednesday, February 11, 2026 at 5 p.m. ET Chief Executive Officer — Leslie Trigg Chief Financial Officer — Renee Gaeta Need a quote from a Motley Fool analyst? Email [email protected] Leslie Trigg: Thanks, Jim. Good afternoon, everyone, and thank you for joining us. 2025 was a year of progress and transformation at Outset Medical, a year where we overcame adversity to emerge with a stronger foundation and even deeper capabilities to help hospitals, health systems, post-acute and home providers improve patient care outcomes at lower cost and with less complexity. During the year, we substantially reduced our cost structure while making significant investments to extend our technology and service leadership. These investments were key to our announcement 2 weeks ago about the FDA clearance of our next-generation Tablo platform. Second, we meaningfully strengthened our team and infused new talent into key leadership roles, in finance, medical affairs and field service. Third, we recapitalized the company with less debt and new capital to fund Outset through cash flow breakeven and beyond. Fourth, we expanded our base of published evidence, demonstrating the significant clinical, operational and financial benefits that can be achieved by in-sourcing with Outset and Tablo. In particular, the clinical value proposition came into clear focus as our customers documented even more evidence of improved clinical outcomes. Fifth, we maintained a very high customer satisfaction or CSAT score, above 95%, for the exceptional customer service we provide. And lastly, we continue to sign new agreements for the in-sourcing of dialysis at new and expansion sites, including at one of the largest national health systems in the country with well over 100 facilities. Tablo is now used at roughly 1,000 acute care sites in the United States. Turning to our financial results for the year, we announced preliminary fourth quarter revenue last month, which came in at the high end of our revised guidance range. At $119.5 million, revenue grew by 5% over 2024 and sets us up for what we anticipate will be an even stronger growth year in 2026. As we have worked toward greater consistency and predictability in our top line results, we continued our steady 5-year expansion of gross margin to finish the year at 39.6% non-GAAP gross margin. Gross margin exiting the year...

Interested in Outset Medical, Inc.? Here are five stocks we like better. Q1 revenue was $27.9 million, down slightly year‑over‑year due to lumpiness in capital order timing, but management reaffirmed full‑year guidance of $125–$130 million and expects the bulk of growth to come in Q3–Q4. Margins and cash improved materially—non‑GAAP gross margin rose 620 bps to 43.8% and non‑GAAP net loss narrowed to $15.4 million—while the company ended the quarter with $161 million in cash and now expects full‑year cash usage of less than $40 million. Next‑generation Tablo is slated for a limited release in Q2 into Q3 with a full launch thereafter, touting hardware/software upgrades and being positioned as the first dialysis system cleared under the FDA’s 2025 cybersecurity requirements, which management says could accelerate replacements and create new EMR integration revenue opportunities. Breakout Momentum Plays You Need to Know About Outset Medical (NASDAQ:OM) reported first-quarter 2026 revenue of $27.9 million, as management pointed to “consistent execution” in console utilization, new customer additions, gross margin expansion, and cash discipline, while acknowledging that capital order timing weighed on results. Chair and CEO Leslie Trigg said the quarter’s revenue was “down slightly from the fourth quarter due to the lumpiness of capital sales,” but emphasized the company “remain[s] confident” in its full-year growth plan, supported by a deep sales pipeline and an upcoming next-generation Tablo launch. → Insider Sales: Top AST SpaceMobile Insider Cuts Postion Over 30% Chief Financial Officer Renee Gaeta said revenue declined 6% year over year from $29.8 million in the first quarter of 2025, “largely due to some lumpiness in the timing of capital orders.” Product revenue was $18.6 million, down 13%, including capital sales of $5.4 million. Consumable sales were “a bit stronger than anticipated” at $13.2 million, Gaeta said. Gaeta added that about $1 million in capital deals shifted out of the first quarter and are expected to close later in the year, noting the company had anticipated this year-over-year dynamic on its prior earnings call. Service and other revenue rose 10% to $9.3 million, and recurring revenue from consumables and service totaled $22.5 million, which Gaeta said was roughly flat sequentially and versus the prior-year period, “both as we anticipate...

SAN JOSE, Calif., May 07, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the first quarter ended March 31, 2026. First Quarter and Recent Highlights Net revenue totaled $27.9 million, a decrease of 6% compared to $29.8 million in the first quarter of 2025. Recurring revenue consisting of Tablo consumables and services was $22.5 million, roughly even with the prior-year period. Gross margin expanded by more than 600 basis points over the prior-year period to 43.4% (43.8% on a non-GAAP basis). Product gross margin of 52.4% and service and other gross margin of 26.7% were record highs. Net cash used during the quarter of $12 million was less than previously forecasted, resulting in a strong cash position, including restricted cash, cash equivalents and short-term investments, of $161 million at quarter-end. “We delivered a solid first quarter and continued to make meaningful progress on our path to profitability, driven by disciplined execution and another quarter of record gross margin performance,” said Leslie Trigg, Chair and Chief Executive Officer. “With utilization strong and service margins expanding, we remain focused on driving broader adoption of Tablo across care settings and confident in our full-year outlook.” First Quarter 2026 Financial Results Revenue for the first quarter was $27.9 million, a decrease of 6% compared to $29.8 million in the first quarter of 2025. Product revenue of $18.6 million decreased 13% from $21.3 million in the first quarter of 2025. Service and other revenue of $9.3 million increased 10% compared to $8.5 million in the first quarter of 2025. Recurring revenue from the sale of Tablo cartridges and service was $22.5 million as compared to $22.7 million in the prior-year period. Gross profit of $12.1 million increased 9% from $11.1 million for the first quarter of 2025. Gross margin was 43.4%, compared to 37.2% in the first quarter of 2025. On a non-GAAP basis, gross margin reached 43.8% as compared to 37.6% in the first quarter of 2025. Product gross profit was $9.7 million, compared to $10.3 million in the first quarter of 2025. Product gross margin was 52.4%, compared to 48.3% in the first quarter of 2025. Service and other gross p...

Image source: The Motley Fool. Thursday, May 7, 2026 at 4:30 p.m. ET Chief Executive Officer — Leslie L. Trigg Chief Financial Officer — Renee M. Gaeta Chief Commercial Officer — Derek Elliott Need a quote from a Motley Fool analyst? Email [email protected] Leslie L. Trigg: Thanks, Jim. Good afternoon, everyone, and thank you for joining us. The first quarter reflected consistent execution across console utilization, new customer additions, gross margin expansion, and disciplined cash management. While variability in capital order timing impacted our capital sales performance in the quarter, we remain confident in our growth plan for the year, supported by the upcoming launch of the next-generation Tableau, a deep sales pipeline, and the addition of an experienced commercial leader in Derek Elliott, who I am pleased to personally introduce to you today. Beginning with the quarter, revenue of $27.9 million was down slightly from the fourth quarter due to the lumpiness of capital sales, but we are confident in our growth plans for the full year. Treatment and service performed exactly as we expected, and we achieved excellent gross margin expansion with product margin reaching over 52%, the result of our ongoing margin expansion programs and mix. More broadly, our end markets remain healthy and providers continue to allocate capital to projects that deliver clear benefits like those we offer. We are reaffirming our annual guidance today because we remain very confident in the depth, diversity, and maturity of our pipeline. In particular, we are in the late stages of closing several large new deals and also an emerging refresh opportunity with existing customers who have older Tableau consoles and intend to buy replacement units in future quarters and years. We had several key wins during the quarter and managed successful go-live implementations at both new customer sites and with existing customers expanding Tableau insourcing to new facilities within their network. A very recent example occurred just a few weeks ago in Texas. Over the course of two days, our team set up dialysis service lines at multiple hospitals owned by one of the largest health systems in the country. These facilities had a total of approximately 400 beds and required support to train the nursing staff, ensure replicable procedures were in place, and prepare the internal team to manage the new...

This article first appeared on GuruFocus. Outset Medical Inc (NASDAQ:OM) is set to release its Q1 2026 earnings on May 7, 2026. The consensus estimate for Q1 2026 revenue is $28.90 million, and the earnings are expected to come in at -$1.01 per share. The full year 2026's revenue is expected to be $126.77 million, and the earnings are expected to be -$4.01 per share. More detailed estimate data can be found on the Forecast page. Warning! GuruFocus has detected 3 Warning Signs with OM. Is OM fairly valued? Test your thesis with our free DCF calculator. Over the past 90 days, revenue estimates for Outset Medical Inc (NASDAQ:OM) have declined from $127.65 million to $126.77 million for the full year 2026, while they have increased from $128.03 million to $140.70 million for 2027. Earnings estimates have improved from -$4.02 per share to -$4.01 per share for the full year 2026 and from -$3.61 per share to -$3.34 per share for 2027. In the previous quarter ending December 31, 2025, Outset Medical Inc's (NASDAQ:OM) actual revenue was $28.87 million, which beat analysts' revenue expectations of $26.65 million by 8.35%. Outset Medical Inc's (NASDAQ:OM) actual earnings were -$1.09 per share, which beat analysts' earnings expectations of -$1.12 per share by 2.68%. After releasing the results, Outset Medical Inc (NASDAQ:OM) was down by 16.30% in one day. Based on the one-year price targets offered by 3 analysts, the average target price for Outset Medical Inc (NASDAQ:OM) is $9.00, with a high estimate of $12.00 and a low estimate of $7.00. The average target implies an upside of 95.65% from the current price of $4.60. Based on GuruFocus estimates, the estimated GF Value for Outset Medical Inc (NASDAQ:OM) in one year is $5.30, suggesting an upside of 15.22% from the current price of $4.60. Based on the consensus recommendation from 4 brokerage firms, Outset Medical Inc's (NASDAQ:OM) average brokerage recommendation is currently 2.3, indicating an "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.

SAN JOSE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM) (“Outset”), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today announced that it will release financial results for the first quarter 2026 after the close of trading on Thursday, May 7, 2026. On the same day, at 1:30 p.m. Pacific time (4:30 p.m. Eastern time), Leslie Trigg, Chair and Chief Executive Officer, and Renee Gaeta, Chief Financial Officer, will host a conference call to discuss financial and operating results. Conference Call Details The conference call will begin at 1:30 p.m. Pacific time (4:30 p.m. Eastern time) on Thursday, May 7, 2026. Those interested in joining the conference call may do so by registering online. Once registered, participants will receive dial-in numbers and a unique pin to join the call. Participants are encouraged to register more than 15 minutes before the start of the call. A live and archived webcast of the event will be available on the “Investors” section of the Outset website at https://investors.outsetmedical.com/. About Outset Medical, Inc. Outset is a medical technology company transforming the dialysis experience across the continuum of care with a first-of-its-kind technology. The Tablo® Hemodialysis System, FDA-cleared for use from hospital to home, is trusted by more than 1,000 U.S. healthcare facilities and has enabled millions of treatments delivered by thousands of nurses. Designed to reduce the cost and complexity of dialysis, Tablo combines water purification and on-demand dialysate production into a single, integrated system that connects seamlessly with Electronic Medical Record systems and a proprietary data analytics platform. This enterprise solution empowers providers to develop an in-house dialysis program where they are in control – enabling better operational, clinical, and financial outcomes. Outset is redefining what’s possible in kidney care through innovation, scale, and a relentless commitment to improving the lives of patients and the professionals who care for them. For more information, visit www.outsetmedical.com. Contact Jim Mazzola [email protected]

Outset Medical, Inc. (NASDAQ:OM) is one of the 7 most volatile stocks under $5 for day trading. On February 12, 2026, Outset Medical, Inc. (NASDAQ:OM) shares received fresh support from analysts despite a decline in price targets after fourth-quarter results that largely met expectations. After the company provided what it considered to be a realistic 2026 target, TD Cowen lowered its target to $12 from $15, and BTIG lowered its target to $15 from $17, both of which kept their ‘Buy’ ratings. In a research note, the BTIG analyst informed investors that this quarter, featuring a stable sales force, an upcoming product, a wide and expanding deal pipeline, robust recurring revenue, and improving margins, will help the company restore credibility. Outset Medical, Inc. (NASDAQ:OM), on February 11, 2026, announced fourth-quarter revenue of $28.90 million, a 2% year-over-year decrease. Accordingly, the total revenue for 2025 came out at $119.50 million, a 5% increase. In addition, the full-year margin improved to 39.10%, and the quarterly gross margin increased by 600 basis points to 42.40%. Meanwhile, cash at year-end was $173 million, and adjusted net loss decreased from $19.30 million to $15.10 million. In addition to outlining plans to launch its next-generation Tablo platform in the second quarter, Outset Medical, Inc. (NASDAQ:OM)’s management projected 2026 revenue of $125 million to $130 million, with a non-GAAP gross margin in the low-to-mid-40% range. Outset Medical, Inc. (NASDAQ:OM), founded in 2003 in San Jose, offers dialysis solutions through its Tablo Hemodialysis System, which enables both acute and home treatment. The company aims to simplify and modernize dialysis care delivery. While we acknowledge the potential of OM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: What Are the Best Stocks to Buy Right Now? and 10 Stocks Under $1 That Will Explode. Disclosure: None.

There's been a major selloff in Outset Medical, Inc. (NASDAQ:OM) shares in the week since it released its annual report, with the stock down 25% to US$3.39. Revenues came in at US$119m, in line with forecasts and the company reported a statutory loss of US$5.37 per share, roughly in line with expectations. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We've gathered the most recent statutory forecasts to see whether the analysts have changed their earnings models, following these results. AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early. After the latest results, the four analysts covering Outset Medical are now predicting revenues of US$126.6m in 2026. If met, this would reflect a credible 6.0% improvement in revenue compared to the last 12 months. Losses are supposed to decline, shrinking 11% from last year to US$4.01. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$127.6m and losses of US$4.02 per share in 2026. See our latest analysis for Outset Medical As a result, it's unexpected to see that the consensus price target fell 11% to US$10.50, with the analysts seemingly becoming more concerned about ongoing losses, despite making no major changes to their forecasts. Fixating on a single price target can be unwise though, since the consensus target is effectively the average of analyst price targets. As a result, some investors like to look at the range of estimates to see if there are any diverging opinions on the company's valuation. There are some variant perceptions on Outset Medical, with the most bullish analyst valuing it at US$15.00 and the most bearish at US$7.00 per share. This is a fairly broad spread of estimates, suggesting that analysts are forecasting a wide range of possible outcomes for the business. Of course, another way to look at these forecasts is to place them into context against the industry itself. It's pretty clear that there is an expectation that Outset Medical's revenue growth will slow down substantially, with revenues to the end of 2026 expected to display 6.0% growth...

Outset posted 2025 revenue of $119.5 million (up 5%), materially expanded non‑GAAP gross margins and narrowed non‑GAAP net loss to $65.4 million, ended the quarter with $173 million in cash and cut operating cash burn to $46 million, which management says is sufficient to reach profitability. The company secured FDA clearance for a next‑generation Tablo platform built to 2025 cybersecurity standards and plans to launch the upgraded system toward the end of Q2, offering upgrades for existing customers and positioning cybersecurity as a competitive advantage. For 2026 Outset guided revenue of $125–$130 million (5–9% growth) with non‑GAAP gross margins in the low‑to‑mid 40% range, expects revenue to accelerate later in the year, lower cash use than in 2025, and noted pipeline diversification though large enterprise deals can have 9–18 month sales cycles. Interested in Outset Medical, Inc.? Here are five stocks we like better. Breakout Momentum Plays You Need to Know About Outset Medical (NASDAQ:OM) highlighted a year of operational progress, continued gross margin expansion, and an upcoming product launch during its fourth-quarter 2025 earnings call, as management emphasized cost reductions alongside investments aimed at extending the company’s technology and service position in dialysis. Chief Executive Officer Leslie Trigg said 2025 was a “year of progress and transformation,” noting the company reduced its cost structure while investing in technology and service capabilities. Trigg also pointed to several developments the company believes strengthen its foundation, including additions in key leadership roles across finance, medical affairs, and field service, and a recapitalization that reduced debt while providing new funding “through cash flow, breakeven, and beyond.” → Once Upon A Farm: Buy the $1B Growth Story? Trigg said the company continued to expand its published evidence base around the benefits of insourcing dialysis with Tablo, and that customer satisfaction remained high, with CSAT above 95%. She added that Outset continued signing new agreements for insourcing dialysis at new and expansion sites, including with “one of the largest national health systems in the country, with well over 100 facilities.” Tablo is now used at roughly 1,000 acute care sites in the U.S., she said. Trigg said Outset received FDA clearance two weeks prior to the call fo...

SAN JOSE, Feb. 11, 2026 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter, Year-End and Recent Highlights Net revenue totaled $28.9 million in the fourth quarter, bringing revenue in 2025 to $119.5 million, a 5% increase over $113.7 million in 2024. Recurring revenue consisting of Tablo consumables and services was $22.5 million in the fourth quarter and grew 6% in 2025 to $88.7 million compared to $83.9 million in 2024. Gross margin expanded by nearly 600 basis points in the fourth quarter to 42.4% (42.9% on a non-GAAP basis). Gross margin for the year of 39.1% (39.6% on a non-GAAP basis) expanded more than 500 basis points from 33.9% in 2024. Year-end cash, including restricted cash, cash equivalents and short-term investments, totaled $173 million. Net cash used in operations in 2025 was $46 million compared to $116 million in 2024. Received clearance from the U.S. Food and Drug Administration for the next-generation Tablo platform, designed for enterprise-level cybersecurity, reliability and connectivity, which is expected to launch in the second quarter. “We enter 2026 standing on a strong foundation for growth, well capitalized, and with a highly differentiated platform to help healthcare providers transform their clinical, operational and financial outcomes by insourcing dialysis with Outset,” said Leslie Trigg, Chair and Chief Executive Officer. Fourth Quarter 2025 Financial Results Revenue for the fourth quarter was $28.9 million, a decrease of 2% compared to $29.5 million in the fourth quarter of 2024. Product revenue was $19.9 million as compared to $21 million in the fourth quarter of 2024. Service and other revenue of $9 million increased 6% compared to $8.5 million in the fourth quarter of 2024. Recurring revenue from the sale of Tablo consumables and services was $22.5 million as compared to $23.7 million in the prior year period. Gross profit of $12.2 million increased 14% from $10.7 million in the fourth quarter of 2024. Gross margin was 42.4%, compared to 36.5% in the fourth quarter of 2024. On a non-GAAP basis, gross margin reached 42.9%, as compared to 38.6% in the fourth quarter of 2024. P...